ClinicalTrials.gg
CompletedNCT02320812Updated Mar 5, 2019Results posted

Safety of a Single, Intravitreal Injection of Human Retinal Progenitor Cells (jCell) in Retinitis Pigmentosa

A Phase 1/2 interventional study of human retinal progenitor cells in Retinitis Pigmentosa (RP), sponsored by jCyte, Inc. Completed at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-03-05.

Sponsored by jCyte, Inc · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
28
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 119 studies in Retinitis Pigmentosa with a site in United States — 20 open to participants now, 44 under way, 6 of them phase 3. Retinitis Pigmentosa · United States.

Enrollment
31st of 78
28 · median 21
Started
2015
with 4 others
Phase 1/2
20 of 119
4 open now
Registered
42nd of 119
by date
Lead sponsor
4 of 119
jCyte, Inc

Among the 119 studies in Retinitis Pigmentosa with a site in United States, this one is the 31st largest by enrollment of the 78 interventional ones that give a count, is one of 5 that started in 2015, is one of 20 in phase 1/2, and was the 42nd registered.

Retinitis Pigmentosa

278 studies on the registry are indexed under Retinitis Pigmentosa; 72 are open to participants now.

Browse Retinitis Pigmentosa studies →

Open to participants now

20 of the 119 studies in Retinitis Pigmentosa with a site in United States are open now. Recruiting first, the newest first:

15 more — sign in →

All 20 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 49 Retinitis Pigmentosa studies recruiting now, 37 (76%) set no upper age limit and 7 (14%) stop at 75 or younger; 16 take children under 18; 10 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 119 studies in Retinitis Pigmentosa with a site in United States, or all of them as a file.
02

Study summary

This study evaluates the safety and potential activity of a single dose of live human retinal progenitor cells (jCell) administered to adults with retinitis pigmentosa. Four different dose levels of cells will be assessed in each of two groups of patients.

Read the detailed description

The primary purpose of this study is to test the safety and tolerability of the administration of a single dose of jCell to adults with retinitis pigmentosa.

The goal of jCell therapy is to preserve vision by intervening in the disease at a time when host photoreceptors can be protected and potentially reactivated.

Human allogeneic retinal progenitor cells will be injected into adults with advanced RP to see if the procedure is safe, if the cells survive, and whether they have any impact on the visual status of the patients.

03

Conditions studied

  • Retinitis Pigmentosa (RP)

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Clinical diagnosis of RP confirmed by electroretinogram (ERG) and willing to consent to mutation typing, if not already done
  • Best corrected visual acuity (BCVA) 20/63 or worse and no worse than hand motions (HM)
  • Adequate organ function and negative infectious disease screen
  • Female of must have negative pregnancy test and be willing to use medically accepted methods of throughout the study

Exclusion criteria

Exclusion Criteria:

  • Eye disease other than RP that impairs visual function
  • Pseudo-RP, cancer-associated retinopathies
  • History of or other end-stage organ disease, or any chronic disease requiring continuous treatment with system , anticoagulants or agents
  • Known allergy to penicillin or streptomycin
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
28 participants (actual)

Study arms

  • Experimental
    Treated subjects

    human retinal progenitor cells

    Biological: human retinal progenitor cells

Interventions

  • Biologicalhuman retinal progenitor cells

    single intravitreal injection of 0.5 - 3.0 million human retinal progenitor cells (hRPC)

    Also known as: jCell

06

What researchers measure

Primary outcomes

  1. Number of Subjects With Adverse Events as a Measure of Safety and Tolerability

    proportion of subjects with treatment emergent adverse events (TEAE), related TEAE and severe TEAE

    Time frame: 12 months

Secondary outcomes

  1. Change in Mean Best Corrected Visual Acuity (BCVA)

    change in mean best corrected visual acuity in test eye versus untreated eye; BCVA is measured using an eye chart and is reported as the number of letters read correctly (ranging from 0 to 100 letters) in the study eye. The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). A positive change from baseline indicates an improvement and a negative change from baseline indicates a worsening. Change between baseline and month 12 is reported.

    Time frame: 12 months

07

Results

Posted Mar 5, 2019

Participant flow

Participant flow — Overall Study
MilestoneTreated Subjects
Started28
Completed28
Not completed0

Outcome measures

PrimaryNumber of Subjects With Adverse Events as a Measure of Safety and Tolerability

proportion of subjects with treatment emergent adverse events (TEAE), related TEAE and severe TEAE

Time frame:
12 months
Reported as:
Count of participants · Participants
Number of Subjects With Adverse Events as a Measure of Safety and Tolerability
ParticipantsTreated Subjects
Subjects with TEAE25
Subjects with related TEAE21
Subjects with grade 3 TEAE1
SecondaryChange in Mean Best Corrected Visual Acuity (BCVA)

change in mean best corrected visual acuity in test eye versus untreated eye; BCVA is measured using an eye chart and is reported as the number of letters read correctly (ranging from 0 to 100 letters) in the study eye. The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). A positive change from baseline indicates an improvement and a negative change from baseline indicates a worsening. Change between baseline and month 12 is reported.

Time frame:
12 months
Reported as:
Mean · number of letters read correctly
Change in Mean Best Corrected Visual Acuity (BCVA)
number of letters read correctly0.5 Million Cells Cohort1.0 Million Cells Cohort2.0 Million Cells Cohort3.0 Million Cells Cohort
Change in Mean Best Corrected Visual Acuity (BCVA)1.4 (-3 to 11)1.0 (-3 to 11)4.8 (0 to 8)9.0 (0 to 12)

Adverse events

Collected over one year following single intravitreal injection of hRPC. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Treated Subjects0/28 (0%)1/28 (3.6%)20/28 (71.4%)
Most frequent serious events
Most frequent serious events
EventTreated Subjects
migratory painMusculoskeletal and connective tissue disorders1/28
Most frequent other events
Most frequent other events
EventTreated Subjects
conjunctival hemorrhageEye disorders10/28
anterior chamber flareEye disorders5/28
eye painEye disorders5/28

Baseline characteristics

Age, Continuous
Age, Continuous(years)Treated Subjects
Mean49.2 ± 14.7
Sex: Female, Male
Sex: Female, Male(Participants)Treated Subjects
Female17
Male11
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Treated Subjects
Hispanic or Latino7
Not Hispanic or Latino21
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Treated Subjects
American Indian or Alaska Native0
Asian4
Native Hawaiian or Other Pacific Islander0
Black or African American0
White24
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(participants)Treated Subjects
United States28
08

Study locations

2 sites
  • The Gavin Herbert Eye Institute, Univ California Irvine
    Irvine, California, United States
  • Retina-Vitreous Associates Medical Group
    Los Angeles, California 90074, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2015, a primary completion of Jul 2017 and a completion of Jul 2017. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2019, 1 year 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 16, 2014
First posted
Dec 19, 2014
Start
Jun 2015
Primary completionActual
Jul 19, 2017
CompletionActual
Jul 19, 2017
Results first posted
Mar 5, 2019
Last update
Mar 5, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 5, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02320812
Lead sponsor
jCyte, Inc
Collaborators
California Institute for Regenerative Medicine (CIRM)
Responsible party
Sponsor
First posted
Dec 19, 2014
Start date
Jun 2015
Primary completion
Jul 19, 2017
Completion
Jul 19, 2017
Results posted
Mar 5, 2019
Last update
Mar 5, 2019

Study contacts

Baruch Kuppermann, MD
principal investigator · Gavin Herbert Eye Institute, UCI, Irvine, CA

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion